

09 September 2024

## The usage of biologic and biosimilar products for Rheumatology and for Axial Spondyloarthritis

**Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

- Abatacept [Orencia] Iv 57, SC 213
- Adalimumab [Humira] 408
- Adalimumab Biosimilars Imraldi 543 Amgevita 291
- Apremilast [Otezla] 24
- Baricitinib [Olumiant] 35
- Bimekizumab [Bimzelx] 18
- Certolizumab [Cimzia] 147
- Etanercept [Enbrel] 113
- Etanercept Biosimilars 349
- Filgotinib [Jyseleca] <5
- Golimumab [Simponi] 95
- Guselkumab [Tremfya] <5
- Infliximab [Remicade] 57
- Infliximab Biosimilars 41 IV <5 SC
- Ixekizumab [Taltz] 113
- Risankizumab [Skyrizi] <5
- Rituximab [MabThera] 78
- Rituximab Biosimilars 162
- Sarilumab [Kevzara] <5
- Secukinumab [Cosentyx] 232
- Tocilizumab [Ro Actemra] 196
- Tocilizumab Biosimilars <5

**09 September 2024**

- Tofacitinib [Xeljanz] 29
- Upadacitinib [Rinvoq] 94
- Ustekinumab [Stelara] 11
- Ustekinumab Biosimilar <5

**Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.**

- Adalimumab [Humira] 68
- Adalimumab Biosimilars 48 Amgevita 104 Imraldi
- Certolizumab [Cimzia] 20
- Etanercept [Enbrel] 16
- Etanercept Biosimilars 56
- Golimumab [Simponi] 22
- Infliximab [Remicade] 11
- Infliximab Biosimilars 9 IV <5 SC
- Ixekizumab [Taltz] 25
- Secukinumab [Cosentyx] 53
- Tofacitinib [Xeljanz] <5
- Upadacitinib [Rinvoq] 11

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.